These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35598317)

  • 1. Evolution and diabetic vasculopathy.
    Yamamoto H; Yamamoto Y
    J Diabetes Investig; 2022 Jul; 13(7):1111-1113. PubMed ID: 35598317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent progress in advanced glycation end products and diabetic complications.
    Vlassara H
    Diabetes; 1997 Sep; 46 Suppl 2():S19-25. PubMed ID: 9285494
    [No Abstract]   [Full Text] [Related]  

  • 3. Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors.
    Vlassara H; Bucala R
    Diabetes; 1996 Jul; 45 Suppl 3():S65-6. PubMed ID: 8674896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetic macrovascular disease: the glucose paradox?
    Libby P; Plutzky J
    Circulation; 2002 Nov; 106(22):2760-3. PubMed ID: 12450998
    [No Abstract]   [Full Text] [Related]  

  • 5. [Oxidative stress in diabetes].
    Mizuta M
    Nihon Yakurigaku Zasshi; 2005 Mar; 125(3):125-8. PubMed ID: 15855729
    [No Abstract]   [Full Text] [Related]  

  • 6. Diabetes and advanced glycation endproducts.
    Vlassara H; Palace MR
    J Intern Med; 2002 Feb; 251(2):87-101. PubMed ID: 11905595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the -429 T/C and -374 T/A receptor for advanced glycation end products promoter polymorphisms in diabetic and nondiabetic subjects with macrovascular disease.
    Hudson BI; Stickland MH; Futers TS; Grant PJ
    Diabetes Care; 2001 Nov; 24(11):2004. PubMed ID: 11679477
    [No Abstract]   [Full Text] [Related]  

  • 8. Expression of receptors for advanced glycation end-products in occlusive vascular and renal disease.
    Bierhaus A; Ritz E; Nawroth PP
    Nephrol Dial Transplant; 1996; 11 Suppl 5():87-90. PubMed ID: 9044315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis.
    Schmidt AM; Yan SD; Wautier JL; Stern D
    Circ Res; 1999 Mar; 84(5):489-97. PubMed ID: 10082470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus.
    Hori O; Yan SD; Ogawa S; Kuwabara K; Matsumoto M; Stern D; Schmidt AM
    Nephrol Dial Transplant; 1996; 11 Suppl 5():13-6. PubMed ID: 9044300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure.
    Ahmad S; Siddiqui Z; Rehman S; Khan MY; Khan H; Khanum S; Alouffi S; Saeed M
    Curr Vasc Pharmacol; 2017; 15(4):352-364. PubMed ID: 28356033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new dark side of the Maillard's products.
    Wautier JL
    Diabetes Metab; 2003 Feb; 29(1):86-7. PubMed ID: 12629454
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulation of RAGE for attenuating progression of diabetic vascular complications.
    Win MT; Yamamoto Y; Munesue S; Saito H; Han D; Motoyoshi S; Kamal T; Ohara T; Watanabe T; Yamamoto H
    Exp Diabetes Res; 2012; 2012():894605. PubMed ID: 22110482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced Glycation End Products and Well-Being in Male Subjects with Type 2 Diabetes Mellitus.
    Papachristou S; Kazakos K; Moschos I; Papazoglou D; Papanas N
    Exp Clin Endocrinol Diabetes; 2024 Jan; 132(1):47-48. PubMed ID: 38134916
    [No Abstract]   [Full Text] [Related]  

  • 15. What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose.
    Yan SD; Stern D; Schmidt AM
    Eur J Clin Invest; 1997 Mar; 27(3):179-81. PubMed ID: 9088851
    [No Abstract]   [Full Text] [Related]  

  • 16. Advanced glycation end-products: a review.
    Singh R; Barden A; Mori T; Beilin L
    Diabetologia; 2001 Feb; 44(2):129-46. PubMed ID: 11270668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes.
    Wendt T; Bucciarelli L; Qu W; Lu Y; Yan SF; Stern DM; Schmidt AM
    Curr Atheroscler Rep; 2002 May; 4(3):228-37. PubMed ID: 11931721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Participation of toxic AGEs (TAGE) in a variety of diseases].
    Takeuchi M
    Nihon Yakurigaku Zasshi; 2012 May; 139(5):193-7. PubMed ID: 22687870
    [No Abstract]   [Full Text] [Related]  

  • 19. RAGE: a novel target for drug intervention in diabetic vascular disease.
    Hudson BI; Schmidt AM
    Pharm Res; 2004 Jul; 21(7):1079-86. PubMed ID: 15290845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association analysis of -429T/C receptor for advanced glycation end products (RAGE) gene polymorphism with type 2 diabetic retinopathy and serum soluble RAGE levels in Pakistani patients.
    Qayyum S; Afzal M; Naveed AK
    J Pak Med Assoc; 2021 Apr; 71(4):1175-1180. PubMed ID: 34125766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.